CD44 and breast cancer: Flow cytometry was used to assess the expression of putative breast cancer stem cell markers of CD44/CD24 in MDA‐MB‐231 cells and displaying a proportion of 93.77% ± 4.04% of the CD44+/CD24− subpopulation (Fig. 1D).